Medical House Share Discussion Threads

[waldron] 07/6/2005 07:06

RNS Number:2108N
Medical House PLC
07 June 2005


For Immediate Release 7 June 2005



The Medical House PLC

Initial deal for AutoSafety Injector (ASI)



The Medical House PLC ("TMH"), (AIM:MLH) the drug delivery and orthopaedic
devices company, is pleased to announce that it has signed a binding term sheet
agreement with a UK-based subsidiary of a major global healthcare products
group. For reasons of commercial and market confidentiality, TMH is not yet in a
position to disclose the identity of the pharmaceutical company.



The agreement relates to TMH's disposable AutoSafety Injector (ASI) to be used
to deliver a currently undisclosed drug. TMH's revenues are anticipated to be in
the region of #3 million over an initial five-year period. Discussions are now
ongoing between the parties to negotiate the definitive terms of a development,
licence and supply agreement. It is anticipated that the collaboration could be
extended in future to other drug products in the pharmaceutical company's
portfolio.



In addition to its needle-free jet injectors, ASI is TMH's recently developed
needle-based disposable autoinjector system. ASI allows injections to be
undertaken by patients themselves or by other non-clinicians such as family
members, friends and colleagues. The ASI incorporates drugs in standard
pre-filled syringes and is suitable for injection of a wide range of
pharmaceuticals to treat a variety of medical conditions. It ensures
comfortable, consistent injection outcomes, whilst also overcoming patients'
aversion to injecting with needles and eliminating risks of needlestick injuries
and disease transmission associated with used needles.



It is estimated that more than 1 billion prefilled syringes are currently used
worldwide. The market for prefilled syringes is believed to be growing at an
annual rate of more than 5%. Drugs supplied in prefilled syringes are primarily
injected for conditions such as rheumatoid arthritis, multiple sclerosis and for
vaccination.



TMH will update the market in due course on details of the final collaboration.



Ian Townsend, Chairman, The Medical House, said:

"We are very pleased to have signed this term sheet agreement with this
pharmaceutical company, as it provides further validation of The Medical House's
ability to deal in the global healthcare arena.



This is a particularly exciting development as it represents the first deal to
bring our disposable autoinjector technology, the ASI, to market for
self-injection. We are presently in discussions with a number of other potential
partners for the ASI who indicate that the simplicity of its design offers many
advantages, such as ease of operation, cost effectiveness and rapid
commercialisation for pharmaceutical company partners. We look forward to
updating the market on details of this collaboration in due course."



-Ends-





For further information

The Medical House PLC
Ian Townsend, Chairman 0114 261 9011
www.themedicalhouse.com
Buchanan Communications

Tim Anderson/Lisa Baderoon/Rebecca Skye Dietrich 020 7466 5000



Notes to Editors:



About The Medical House - Market Background



TMH has progressively been developing a range of needle-free devices which are
already successfully used in the market. TMH's SQ-PEN needle-free device has
great potential in drug delivery worldwide. TMH also has several distribution
agreements in place for the insulin market for its range of reusable needle-free
injectors.



In February 2004, TMH announced a license and supply agreement with Dechra Plc
for needle-free injection system for use with pet animals.



In January 2005 TMH announced an agreement which it has signed with Serono, to
develop and license a new needle-free delivery system for the delivery of
Serono's Human Growth Hormone products.



In February 2005 TMH announced a 10-year agreement which it has signed with
BioPartners GmbH, to supply its GH1 needle-free system for the delivery of
BioPartners' Human Growth Hormone products.



The market for Human Growth Hormone drugs is expected to reach $2.2 billion by
2006 according to AS Insights.




This information is provided by RNS
The company news service from the London Stock Exchange
END

MSCUNRBRVVRNRAR

[grupo] 22/2/2005 07:48

LOND0N (AFX) - The Medical House PLC announced it has signed a 10-year
licence and supply agreement with BioPartners GmbH for a needle-free delivery
system for human growth hormone.
Financial terms of the deal were not disclosed, however based on sales
volumes of needle-free devices, the company projects income for the contract of
14 mln stg, of which 3 mln stg relates to the first five years.
These figures exclude consumable items, such as nozzles and adaptors, which
need to be replaced on a regular basis.
The orthopaedic devices and drug delivery company said the agreement covers
its GH1 reusable, spring-powered, needle-free delivery system for the delivery
of BioPartners' human growth hormone product, Valtropin.
The two companies are also exploring the use of The Medical House's new drug
delivery systems, including the disposable AutoSafety Injector (ASI), with
BioPartners' sustained release formulations of biopharmaceuticals.
"This solidifies The Medical House's reputation as a world leader in the
area of drug delivery devices and we look forward to a long and successful
partnership with BioPartners," said Ian Townsend, executive chairman of The
Medical House.
[e-mail]
el/ak






Medical House(MLH)

[waldron] 21/2/2005 08:01

LONDON (AFX) - Medical House PLC six months to December 31 2004
Sales - 4.56 mln stg vs 2.22 mln
Pretax profit - 46,000 stg vs loss 344,000
Operating profit - 141,000 stg vs loss 267,000
EPS - 0.08 pence vs loss per share 0.59

vjt/

[waldron] 21/2/2005 07:59

LONDON (AFX) - The Medical House PLC said it expects trading in the second
half to continue to perform strongly, as the orthopaedic devices and drug
delivery company announced a maiden profit in the six months to Dec 31 2004.
Sales jumped by 100 pct to 4.5 mln stg from 2.2 mln stg, and the group
turned in a maiden operating profit of 141,000 stg, compared with a loss of
267,000 stg in the same period of last year.
The group, which joined AIM in 2004, reported a maiden pretax profit of
46,000 stg against a loss of 344,000 stg.
"Eurocut, our orthopaedic division has shown record turnover growth and the
deal with Serono has validated our drug delivery device technology on a global
scale," commented executive chairman, Ian Townsend.
"Medical House is now in a strong position to capitalise on opportunities in
both the orthopaedic and drug delivery divisions of our business."
The company attributed its improved performance to a major investment
programme over the last two years. As a result of increasing the size of the
production facility, as well as significant investment in new plant, Eurocut has
been able to benefit from the strong demand in the orthopaedic market.
[e-mail]
el/ak

[waldron] 21/2/2005 07:54

RNS Number:8089I
Medical House PLC
21 February 2005


For Immediate Release 21 February 2005


The Medical House PLC

Interim Results for the six months ended 31 December 2004

"Maiden pre-tax profit"


The Medical House PLC ("TMH"), (AIM:MLH) the orthopaedic devices and drug
delivery company, announces its interim results for the six months ended 31
December, 2004.


* Financial Performance

- 100% increase in turnover to #4.5m (2003: #2.2m)

- Maiden Operating profit of #141,000 (2003: #267,000 loss)

- Maiden pre-tax profit of #46,000 (2003: #344,000 loss)


* Orthopaedic Instruments

- Record turnover of #4.35m (2003: #2.17m)

- Operating Profit increased to #710,000 (2003: #293,000)

- First supply agreement for TMH with DePuy, a division of J&J

- Current sales underpins group profitability

- Future capacity increase guaranteed by land purchase


* Drug Delivery Systems

-#4.3m deal with Serono, a top 10 global biotechnology company

- Sales ahead at #206,000 (2003: #50,000)


Executive Chairman, Ian Townsend, said:

"I am delighted with the company's progress over the last six months. Eurocut,
our orthopaedic division has shown record turnover growth and the deal with
Serono has validated our drug delivery device technology on a global scale.
Medical House is now in a strong position to capitalise on opportunities in both
the orthopaedic and drug delivery divisions of our business."


For further information:


The Medical House PLC tel: [phone]
Ian Townsend, Executive Chairman www.themedicalhouse.com

Buchanan Communications tel: [phone]
Tim Anderson / Rebecca Skye Dietrich /Lisa Baderoon


Business Review


Overview


The Medical House specialises in the development and manufacture of innovative
medical devices.


Our principal operating businesses are:


1. Design and manufacturing surgical instruments, primarily for the
orthopaedic market:

Eurocut Limited

2. Drug Delivery Systems: Medical House Products Limited


We are pleased to report that both divisions produced a strong performance in
the six months under review. It is very satisfying and pleasing to see the hard
work and investment of previous years being rewarded by significant growth in
sales and profits.


Group Financials


The Group is reporting its first interim profit at the pre-tax and operating
levels since joining AIM in September 2000. Pre-tax profit is #46,000 compared
to a loss for the same period in 2003 of #344,000. Operating profit is #141,000
(2003 : #267,000 loss). The profit is the result of the 100% increase in
turnover compared to 2003. Turnover reached #4.5m up from #2.2m.


Orthopaedic Division : Eurocut


Our orthopaedic division performed very strongly. Sales were #4,350,000 (2003
#2,174,000). These higher sales resulted in a significant increase in operating
profits at #710,000 (2003 #293,000). Margins were down slightly due to a higher
proportion of work being subcontracted, in order to avoid production bottlenecks
brought about by the record order book.


The improved performance comes as a result of the major investment programme
carried out during the last two years. As a result of increasing the size of
the production facility, together with significant investment in new plant,
Eurocut has been able to benefit from the strong demand in the orthopaedic
market. As well as a general increase in the number of orthopaedic procedures
this division has gained from a growing trend towards image guided and minimally
invasive procedures. We were very pleased to announce in January a supply
agreement with Depuy whereby we will maintain stocks of their Image Guided
System in return for guaranteed future orders. This has the benefit of securing
supply for Depuy and securing future orders for the company. Success in this
initiative will result in us seeking to introduce more products to this type of
arrangement.


With the rapid growth in our orthopaedic business, we took the opportunity in
January 2005 to acquire the adjacent land to our Newhall Road premises in
Sheffield. The land cost #375,000 and we are currently awaiting building
designs from our architects. Although the company may fund the initial
development costs, it is anticipated that a sale and leaseback arrangement will
enable the group to retain all its liquid resources for investment in working
capital and new equipment.


Drug Delivery Division: Medical House Products


Sales in the six months to 31 December 2004 were well ahead at #206,000 (2003:
#50,000). The increase is due to the improved level of sales of the mhi-500
mainly in the UK. However, during the course of 2005 the mhi-500 will be
replaced with the SQ-Pen for which we have much greater international sales
growth potential.


Under our Bioject licence agreement we are limited to selling the mhi-500 for
insulin only, with no sales outside Europe including Egypt being allowed. On
the other hand the SQ-Pen will be sold to a broader international market through
our thirteen overseas distributors and, whilst they all have samples of the
products, it is too early to say how the device will be received in each of
their markets. Nevertheless, we expect sales of the SQ-Pen to develop steadily
throughout 2005. Furthermore, we also expect sales of the SQ-Pen to benefit
from the agreements we have with both Dechra and BioPartners. Little benefit
however will be seen in the current financial year from sales to these two
companies and it is expected that more meaningful sales will come in 2005/6
onwards.


The highlight of the period under review was the #4.3m development and supply
agreement made with Serono, for the supply of the human growth hormone, using
Medical House's needle-free injection device and related consumables. This
agreement with Serono, a top 10 global biotechnology company, will have a
significant impact on the future sales growth and reputation of Medical House
Products.


Finally, we continue to be very positive about the prospects for our disposable
auto-injector device (ASI) and discussions continue with a number of
organisations for use of ASI in a variety of applications, including emergency
use in the event of bio-terrorism attack.


Outlook for the Full Year


With a sizeable order book at Eurocut and increasing demand for our drug
delivery systems we expect trading in the second half to continue to perform
strongly. All the achievements we have made and continue to make would not be
possible without a committed Board of Directors and workforce all of whom
deserve our gratitude.


Lastly, may I once again thank all our shareholders for their continued support.


Ian Townsend

Executive Chairman

21 February 2005

[whitebicycle] 18/2/2005 08:59

Analyst reports are now available on what looks to be an updated company website.

[whitebicycle] 04/2/2005 20:22

muddy, that was one of the design points of the MHI 500. Bioject failed to realise that diabetics suffer from poor eyesight and were not happy with some of the features. More fool them.
It's just as well MLH have the surgical instrument side as needle free has been hard work for any of the contenders and a few have gone to the wall.

[muddy waters] 03/2/2005 11:31

If the needle free works, and it does seem to, the future is massive. Its not just for the 'needle wary'. Because diabetics despite injecting insulin, may still have raised blood glucose levels, (especially the elderly), the injection sites can easily become infected and tissue necrosis sets in leaving nasty festering sores. That requires doctors, anti-biotics, wound dressings etc.
Now all that's needed is a way of delivering insulin safely to people with poor eyesight.

[maywillow] 25/1/2005 08:13

LONDON (AFX) - Medical House PLC said it has won a deal worth 850,000 stg in
the first year to manufacture and supply instruments used in image guided knee
surgery for Johnson & Johnson unit DePuy International Ltd.
The deal between DePuy and Medical House unit Eurocut Ltd is for a minimum
period of one year, but Medical House said it expects it to become a long-term
relationship.
[e-mail]
lam

[waldron] 11/1/2005 10:31

LONDON (AFX) - The Medical House (TMH) made headway, climbing 3-1/2 pence to
72 after the company revealed that its partner in a 4.3 mln stg contract,
announced in September, is Serono, the global biotechnology leader.
Under the five year contract, TMH will manufacture and supply a reusable,
user filled needle-free injection device and related consumables.
The state of the art needle-free injector is to be developed by TMH with
development costs of ?435,000 being contributed by Serono.
The drug to be delivered is human growth hormone. Worldwide sales of this
product, which was first registered in 1988, were more than 240 mln usd in 2003.
TMH will be able to provide the needle-free injector to pharmaceutical
companies for the delivery of other drugs subject to certain Serono rights of
first refusal.

fjb/vjt/

[whitebicycle] 25/11/2004 16:40

"T" trade for 150,000 announced after the close. Not commented on these for a while but trading volumes have risen slightly over the last couple of weeks.Beats looking at a blank row on ADVFN and wondering why the price has been marked down.

[whitebicycle] 30/10/2004 13:31

Mentioned in the FT London markets section, basically cut and pasted from the RNS.

[whitebicycle] 03/10/2004 20:31

The publicity MLH have had recently can't have been much better. It's been a long wait for those that have stuck it out. I'm not about to cash in yet given that the fair value is now 100p a share.

[v0d00child] 24/9/2004 22:27

September 23, 2004

Talking points

Smaller stock to watch

The Medical House (TMH), the AIM-listed drug delivery firm, rose 3½p to 57p on the signing of a long-awaited deal with an unnamed large drugs group to develop a new delivery system. TMH, which files full-year results today, said the deal's minimum value was expected to be $7.5 million (£4 million) over five years. Code Securities raised its target from 55p to 100p.

[whitebicycle] 24/9/2004 21:05

From the Telegraph Questor column.


Medical House is a shot in the arm

Hands up if you don't like needles! While you are waving your arms in the air, you might like to vote for Medical House, which has managed to do the thing that rival drug delivery companies never managed.

Powderject and Weston Medical were two companies that were founded on the dream of producing needle-free technologies, but neither of them delivered. Weston went bust, and Powderject, rather cleverly, used its much-hyped share price to buy vaccines that would actually sell.

So it has been up to Medical House to pioneer a needle-free syringe, as well as more standard retractable needle technology. The NHS already uses its syringes for some insulin, although sales have been disappointing. However, a deal this week makes the company look a whole lot more exciting.

It has hooked up with a large drug company (no names) that wants to launch a drug using the Medical House technology. The deal, we are told, is worth a minimum of $7.5m, which is transformative for a company with a market capitalisation of £34m. It hopes more will follow.

As well as the space-age stuff, Medical House has a small business making orthopaedic instruments for hip replacement that provides most of its turnover.

Yesterday the business announced full-year sales of £5.6m against £5.2m, while losses narrowed slightly to £479,000. Analysts expect a profit in 2006. The shares rose 2.5 to 59.5p.

The risks with this company are the same as for any tiny business. If things go wrong, they go very, very wrong - and big drug companies are not known for their kindness to their weaker brethren.

But if you don't mind being at the sharp end, Medical House might be worth a shot.

[whitebicycle] 22/9/2004 11:47

LONDON (AFX) - Shares in The Medical House PLC are still a 'buy' in the wake
of today's new drug delivery device deal, according to Code Securities analyst
Michael King. He is cranking up his price target to 100 pence from just 55.
And more announcements of deals in the short to medium term could result in
further upside, King said.
The analyst has assumed that initial sales of the new deal impact in the
year to June 2006, raising his Drug Delivery sales forecast for that year to 2.0
mln stg from 1 mln and raising sales estimates for the year to June 2007 to 4.5
mln from 2 mln, and for 2008 to 7.5 mln from 4 mln.
King now forecasts drug delivery operating profit of 300,000 stg in the year
to June 2006 (up from 100,000 stg loss), rising to 900,000 stg in 2007 and 1.5
mln in 2008 (up from 300,000 stg and 800,000 stg respectively).
This deal not only brings forecasts for the Drugs Delivery business into
profit a year earlier than previously expected, but it also validates further
The Medical House drug delivery technology, raising hopes that more deals could
follow, said King.
Other deals, not yet factored into the analyst's forecasts, could add
further to the company's potential. These, he said, include an AutoSafety
Injector being developed for an undisclosed partner, for which further details
could be released before the end of this year, and a deal with Dechra for pet
animal use.
King has also raised his orthopaedic sales forecasts for the year to June
2005 to 8 mln stg from 7 mln, and operating profit forecast to 1.55 mln from
1.35.
Following the new deal, the analyst has substantially raised his group
forecasts, with total sales estimates for the year to June 2005 up 1 mln stg to
8.5 mln and net income up 200,000 stg to 270,000 stg.
King values the orthopaedics business at about 35 mln stg and the Drug
Delivery franchise at 25 mln, including a nominal 5 mln for existing but
undisclosed deals, giving a fair value of 100 pence a share.
The Medical House shares stood 3-1/2 pence firmer at 57 by 11.17 am.
fjb/ab

[ariane] 22/9/2004 08:25

LONDON (AFX) - Medical House PLC, the orthopaedic devices and drug delivery
company, announced an agreement with an unnamed global pharmaceutical company to
develop a new device delivery system for use with a currently undisclosed drug.
It expects the five-year exclusive deal to have a minimum value of 7.5 mln
usd.
Medical House would receive approximately 750,000 usd in development costs
for the new delivery system and would be free to licence the system to other
companies for additional indications.
Medical House chief executive Ian Townsend said: "I look forward to this
producing a substantial income stream for TMH over the coming years and the
platform technology being developed is expected to have applications for a whole
range of new and existing drugs.
"It is also pleasing that this comes at a time when our orthopaedic division
is trading at record levels with a 5 mln stg order book," he added.
[e-mail]
ak/

[whitebicycle] 22/9/2004 07:56

Now I did say something was in the wind and MLH haven't dissapointed again.

[whitebicycle] 15/9/2004 20:26

thanks for the reply, ring them up I have twice in the past. Up again today, must come up on someones radar soon, I would think most short termers would be out by now as it rarely trades and the price has been eroded over the last few months. Still think there is something due.

[briano] 14/9/2004 22:45

Hi whitey, just thought I'd let you know you are not totally alone on here. I've held for 3 months. Got in because I think needleles injection side could really take off. Sad to say, but diabetes affects many millions worldwide (and is growing at an alarming rate), and for those who have to inject regularly several times a day, a needleless solution must be fantastic. There is competition, but the market is so vast that many companies could do extremely well. Results will be interesting, and I expect a figure marginally either side of break even, but more important will be news of new deals. Have you any idea why results are so long after year end (4.5 months last year)?

[whitebicycle] 14/9/2004 14:39

Up another 2p, methinks something is in the wind.

[whitebicycle] 13/9/2004 16:09

Spikes up on no volume, another RNS coming?

[whitebicycle] 14/7/2004 09:57

Could mean a profit, they have said the previous annual turnover has been acheived in sixmonths. Just been talking about it on the ADVFN Intercast.
Good to see the needleless side of it making some headway at last. On that side of things I would say they have surpassed Bioject.

[pugugly] 14/7/2004 09:15

Anyone know what were market expectatiosn - Does thsi mean a smaller loss? Or could it actually be breakeven+ Very cautious wording (IMO & dyor)